Evidence map›Paper›PMID 28984429›Full record

ArticleHIV medicine2018

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.

A Cozzi-Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, H Sambatakou, G Fätkenheuer, I Yust and 12 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01078233 (Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01078233 completednot on this map

Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period

TypeobservationalSponsorMerck Sharp & Dohme LLCRan2008 to 2014Enrolled6,617ConditionsHIV-1 Infections
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 19 institutions in 18 countries.

A Cozzi-LepriCentre for Clinical Research, Modelling and Epidemiology, Research Department of Infection and Population Health, Institute for Global Health, University College London Medical School, Royal Free Campus, London, UK.
R ZangerleMedical University Innsbruck, Innsbruck, Austria.
L MachalaDepartment of Infectious and Tropical Diseases, Third Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague, Czech Republic.
K ZilmerWest-Tallinn Central Hospital, Tallinn, Estonia.
M RistolaHelsinki University Hospital, Helsinki, Finland.
C PradierL'Archet 1 Hospital, University of Nice Sophia-Antipolis, Nice, France.
O KirkRigshospitalet, University of Copenhagen, Copenhagen, Denmark.
H SambatakouIppokration General Hospital, Athens, Greece.
G FätkenheuerDepartment of Internal Medicine 1, University Hospital of Cologne, Cologne, Germany.
I YustIchilov Hospital, Tel Aviv-Yafo, Israel.
P SchmidKantonsspital St. Gallen, St. Gallen, Switzerland.
M GottfredssonFaculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland and Landspitali University Hospital, Reykjavík, Iceland.
I KhromovaCentre for HIV/AIDS and infectious diseases, Kaliningrad, Russian Federation.
D JilichDepartment of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague, Czech Republic.
R FlisiakDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
J SmidtIda-Viru Central Hospital, Kohtla-Jarve.
B RozentaleInfectology Center of Latvia, Riga, Latvia.
R RadoiDr. Victor Babes Hospital, Bucureşti, Romania.
M H LossoHospital J.M. Ramos Mejia, Buenos Aires, Argentina.
J D LundgrenRigshospitalet, University of Copenhagen, Copenhagen, Denmark.
A MocroftCentre for Clinical Research, Modelling and Epidemiology, Research Department of Infection and Population Health, Institute for Global Health, University College London Medical School, Royal Free Campus, London, UK.
EuroSIDA Study Group
Charles University · CZRigshospitalet · DKCentral State Hospital · USCentre for Prevention and Control of AIDS and Infectious Diseases · RUEast Tallinn Central Hospital · EEHelsinki University Hospital · FIHippocration General Hospital · GRHospital Ramos Mejía · ARInnsbruck Medical University · ATKantonsspital St. Gallen · CHMedical University of Białystok · PLSpitalul Clinic Dr. Victor Babes · ROTel Aviv Sourasky Medical Center · ILThe Royal Free Hospital · GBUniversité Côte d'Azur · FRUniversity College London · GBUniversity Hospital Cologne · DEUniversity of Iceland · ISUniversity of Latvia · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThere are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association.

methodsThe EuroSIDA cohort was divided into three groups: those starting RAL-based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression.

resultsThe RAL cohort included 1470 individuals [with 4058 person-years of follow-up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non-AIDS-related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95-1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37-2.61). In intention-to-treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84-1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90-1.61) and 0.83 (95% CI 0.70-0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47-1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65-1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53-1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76-1.72 for RALvs. CONC).

conclusionsWe found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.

Indexed as

AdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedNeoplasmsProspective StudiesRaltegravir PotassiumRisk AssessmentSurvival AnalysisAnti-Retroviral AgentsRaltegravir Potassiumobservational treatment comparisonpropensity scoresRaltegravirrisk of cancersurvival

Identifiers

PMID28984429
PMCPMC5813233
OpenAlexW2761058079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.